logo
logo

Neonatal Diagnostics Company Infandx Ag Closes Oversubscribed Second Tranche Of Series A

Mar 15, 2022•over 3 years ago

Round Type

series a

Description

Cologne, Germany, and Boston, MA, USA, March 15, 2022 – InfanDx AG, a privately-held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the second closing of its Series A financing round, raising approximately EUR 2 million in additional proceeds from new and existing investors. A first closing of the Series A totaling about EUR 4 million was completed in July 2021. The second tranche of this Series A was placed under the same conditions as the first tranche and oversubscribed by more than 50% based on strong investor interest.

Company Information

Company

Infan Dx

About

The Company ticks all our boxes for ethical investments with the prospect of high societal impact,” commented Wilhelm Grauer, Managing Director of FIL Bros. Capital GmbH. “With this second oversubscribed closing, we responded to unsolicited interest by current and new shareholders to invest into InfanDx, reflecting the excellent progress of the Company in executing its strategy and business plan,” said Wolfgang Kintzel, Chairman of InfanDx´ Supervisory Board. These patient cohorts provide InfanDx with the opportunity to achieve highest levels of validation of the biomarkers and the corresponding diagnostic tests in development.